ARA-290

The design problem it solves. Erythropoietin is strongly tissue-protective in models of nerve, kidney, heart and brain injury. It is also the hormone that makes red blood cells, and giving it to people who are not anaemic raises haematocrit and causes clots. The structural insight behind ARA-290 is that these two activities live on different faces of the molecule and run through different receptors: erythropoiesis through the homodimeric erythropoietin receptor, tissue protection through a heterocomplex of that receptor with the beta common receptor, CD131 - the so-called innate repair receptor. ARA-290 is an 11-residue peptide mimicking helix B's surface, which engages the second receptor and not the first [1].

The trials. A randomised double-blind pilot gave 22 sarcoidosis patients with small fibre neuropathy symptoms 2 mg intravenously three times weekly for four weeks; it was safe and reduced symptoms [5]. A larger blinded placebo-controlled trial used 28 days of daily subcutaneous dosing and found significantly improved neuropathic symptoms, increased corneal small nerve fibre density, changed cutaneous temperature sensitivity and increased 6-minute walk distance [2]. A multicentre dose-ranging trial compared 1, 4 and 8 mg daily against placebo: the placebo-corrected change in corneal nerve fibre abundance was significant at 4 mg (697 µm², 95% CI 159-1236, P = 0.012) but not at 1 mg or 8 mg, and intraepidermal GAP-43-positive fibres increased in the 4 mg group. Pain intensity fell in the 4 mg group but did not reach significance (P = 0.157) [3].

In type 2 diabetes with painful neuropathy, 28 days of self-administered 4 mg daily improved HbA1c and lipid profiles across a 56-day observation period, significantly improved PainDetect scores, and increased corneal nerve fibre density in those who started most impaired [4].

Why small fibre neuropathy matters here. It is a condition where almost nothing works; current treatment of the sarcoidosis-associated form is immune suppression and symptomatic relief, and is described in the literature as typically unsatisfactory [2]. Corneal confocal microscopy gives an objective structural readout, which is more than most neuropathy trials have [6].

What has not happened. No phase 3. The first positive randomised result was published in 2012 [5]; reviews were describing it as a promising investigational drug in 2014 [7] and diabetic neuropathy reviews were still waiting in 2021 [8]. Preclinical work has continued across diabetic wound healing [9], colitis [10], retinal ischaemia [11], cisplatin nephrotoxicity [12], doxorubicin genotoxicity [13] and haemolytic-uraemic syndrome [14]. That is a lot of preclinical breadth and not much clinical depth.

Erythropoietin's tissue-protective effects require a receptor complex distinct from the erythropoietic one: the erythropoietin receptor paired with CD131, the beta common receptor shared by the IL-3, IL-5 and GM-CSF receptors. This heterocomplex is expressed on injured and stressed tissue rather than on erythroid precursors [1][9].

ARA-290 reproduces the relevant surface of helix B and activates that complex selectively. Downstream it dampens innate immune activation [10] and promotes repair - in genetically diabetic mice it restored impaired wound healing through EPOR-beta common receptor activation [9], and it enhanced the vasoreparative capacity of endothelial colony-forming cells in ischaemic retina [11]. A TRPV1-mediated route has been proposed for its analgesic action, which would connect the immune and nociceptive arms [15].

The most unusual feature is temporal. The peptide is cleared quickly, but the review literature describes long-lasting effects from brief exposure - the switch metaphor [1]. That is consistent with the trials, which dosed for 28 days and measured structural nerve changes, but it also means pharmacokinetics tell you very little about how to dose it, and no study has systematically tested duration.

An 11-residue peptide given by subcutaneous injection in the later trials and intravenously in the first [2][5]. Cibinetide is the international nonproprietary name; ARA-290 is the development code. It is sometimes referred to in the mechanistic literature as pyroglutamate helix B surface peptide, pHBSP [14].

The trials consistently report it as safe over 28-day courses. The pilot trial concluded ARA-290 appears safe in sarcoidosis patients [5]; the phase 2 in type 2 diabetes identified no potential safety issues [4].

The central safety argument is structural: because it does not activate the erythropoietic receptor, it does not raise haematocrit, and therefore does not carry the thrombotic risk that limits erythropoietin in non-anaemic patients [1]. That is a designed-in property supported by the animal and clinical data, not an incidental observation.

What that safety record does not cover: total exposure across all published trials is on the order of a hundred patients for 28 days each. There is no long-term data, no data on repeated courses, and no post-marketing surveillance because it has never been marketed. A peptide that dampens innate immune function [10] is one where long-term immune consequences would be worth measuring, and nobody has.

No interaction studies have been published. In the type 2 diabetes trial participants continued their usual diabetes medication and HbA1c improved [4], which is the closest thing to a combination result in the literature.

Mechanistically it does not overlap with erythropoietin-stimulating agents in the way the shared name might suggest - it deliberately avoids the receptor those act on [1].